487 results about "Drug Dissolution" patented technology

Drugs, especially low aqueous solubility drugs, are provided in a porous matrix form, preferably microparticles, which enhances dissolution of the drug in aqueous media. The drug matrices preferably are made using a process that includes (i) dissolving a drug, preferably a drug having low aqueous solubility, in a volatile solvent to form a drug solution, (ii) combining at least one pore forming agent with the drug solution to form an emulsion, suspension, or second solution and hydrophilic or hydrophobic excipients that stabilize the drug and inhibit crystallization, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of drug. Hydrophobic or hydrophilic excipients may be selected to stabilize the drug in crystalline form by inhibiting crystal growth or to stabilize the drug in amorphous form by preventing crystallization. The pore forming agent can be either a volatile liquid that is immiscible with the drug solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. The resulting porous matrix has a faster rate of dissolution following administration to a patient, as compared to non-porous matrix forms of the drug. In a preferred embodiment, microparticles of the porous drug matrix are reconstituted with an aqueous medium and administered parenterally, or processed using standard techniques into tablets or capsules for oral administration.

The present invention relates to liquid sustained release suspension dosage forms comprising ionized forms of water-soluble drugs. In particular, the invention encompasses a liquid form controlled release drug composition comprising a dispersed phase comprising an ion-exchange matrix drug complex comprising a pharmaceutically acceptable ion-exchange matrix and a water-soluble electrolytic drug associated with the ion-exchange matrix, wherein the surface charge of the ion-exchange matrix is opposite that of the electrolytic drug wherein the dispersed phase further comprises a non-electrolytic, soluble component having low molecular weight and a diffusion controlling membrane and a dispersion medium substantially free of diffusible counterions, further comprising an excipient capable of associating with water and impeding water activity such that drug dissolution is inhibited prior to administration. The invention also provides methods for preparing such compositions and methods of treatment.

Among the conventional processes for producing solid dispersion, the solid dispersion obtained by a solvent method is excellent in terms of solubility and bioavailability of a poorly soluble drug. However, due to frequent uses of organic solvents in the solvent method, problems have arisen such as organic solvent residue in products, environmental pollution and operational safety as well as corporate problems such as capital investment and the like required to avoid such events. The present invention provides a process for preparing pharmaceutical solid preparations without use of organic solvents frequently used in conventional solvent methods. Specifically, the present invention provides a process for producing a pharmaceutical solid preparation, which is formulated by spraying a solution wherein a poorly soluble drug is dissolved in a plasticizer, and an aqueous solution and / or water dispersion of a water-soluble polymer from nozzle outlets simultaneously and separately in the process for producing the pharmaceutical solid preparation.

The invention provides an Erdosteine composition which consists of the following components by weight portions: 130 to 170 portions of Erdosteine, 35 to 65 portions of lactose, 30 to 70 portions of microcrystalline cellulose, 20 to 40 portions of low substituted hydroxypropyl cellulose, 1 to 5 portions of acesulfame, 10 to 30 portions of sodium carboxymethyl starch and 0.1 to 0.5 portions of magnesium stearate; the invention also provides a preparation method of the Erdosteine composition, comprising the following steps of: preparing materials and pelleting; mixing the Erdosteine and the low substituted hydroxypropyl cellulose evenly, then grinding, adding the sodium carboxymethyl starch, adding absolute ethyl alcohol, wet-mixing, cutting, drying, granulation and tabletting; mixing granules and microcrystalline cellulose evenly, adding the lactose, the acesulfame and the magnesium stearate for pelleting, subpackaging and obtaining the Erdosteine composition. The Erdosteine compositionhas good dispersible uniformity and high drug dissolution efficiency.